MX2012007416A - Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis. - Google Patents
Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis.Info
- Publication number
- MX2012007416A MX2012007416A MX2012007416A MX2012007416A MX2012007416A MX 2012007416 A MX2012007416 A MX 2012007416A MX 2012007416 A MX2012007416 A MX 2012007416A MX 2012007416 A MX2012007416 A MX 2012007416A MX 2012007416 A MX2012007416 A MX 2012007416A
- Authority
- MX
- Mexico
- Prior art keywords
- angiogenesis
- compositions
- treatment
- methods
- eye diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere generalmente a composiciones y métodos de tratamiento y/o prevención de enfermedades oculares relacionadas con la angiogénesis que emplean dosis bajas de variantes de rodostomina y, en particular, dosis bajas de una proteína de fusión que comprende una variante de rodostomina, en la cual la variante de rodostomina está conjugada con una variante de albúmina sérica humana (HSA) en donde el residuo cisteína en la posición 34 de la secuencia de aminoácidos de la HSA ha sido reemplazado con serina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28962409P | 2009-12-23 | 2009-12-23 | |
PCT/US2010/061738 WO2011079175A1 (en) | 2009-12-23 | 2010-12-22 | Compositions and methods for the treatment of angiogenesis-related eye diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012007416A true MX2012007416A (es) | 2012-07-23 |
Family
ID=44151942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012007416A MX2012007416A (es) | 2009-12-23 | 2010-12-22 | Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis. |
Country Status (14)
Country | Link |
---|---|
US (1) | US9044436B2 (es) |
EP (1) | EP2515926A4 (es) |
JP (1) | JP5739908B2 (es) |
KR (1) | KR20120130752A (es) |
CN (1) | CN102883738A (es) |
AR (1) | AR079706A1 (es) |
AU (1) | AU2010336475A1 (es) |
BR (1) | BR112012015188A8 (es) |
CA (1) | CA2782796A1 (es) |
MX (1) | MX2012007416A (es) |
NZ (1) | NZ600544A (es) |
RU (1) | RU2012131251A (es) |
TW (1) | TWI581801B (es) |
WO (1) | WO2011079175A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3243835B1 (en) | 2009-02-11 | 2024-04-10 | Albumedix Ltd | Albumin variants and conjugates |
WO2011011315A1 (en) * | 2009-07-20 | 2011-01-27 | National Cheng Kung University | POLYPEPTIDES SELECTIVE FOR AV β3 INTEGRIN CONJUGATED WITH A VARIANT OF HUMAN SERUM ALBUMIN (HSA) AND PHARMACEUTICAL USES THEREOF |
GB2488077A (en) | 2009-10-30 | 2012-08-15 | Novozymes Biopharma Dk As | Albumin variants |
JP5969458B2 (ja) | 2010-04-09 | 2016-08-17 | アルブミディクス アクティーゼルスカブ | アルブミン誘導体及び変異体 |
US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
MX2014010278A (es) | 2012-03-16 | 2015-03-05 | Novozymes Biopharma Dk As | Variantes de albumina. |
CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
KR101724129B1 (ko) * | 2014-03-28 | 2017-04-10 | 연세대학교 산학협력단 | Rgd 모티프를 포함하는 펩타이드 또는 단백질을 포함하는 신경염증 예방, 억제 또는 치료용 조성물 |
AU2015305299B2 (en) * | 2014-08-22 | 2018-11-01 | National Cheng Kung University | Disintegrin variants and pharmaceutical uses thereof |
KR101832121B1 (ko) | 2014-12-31 | 2018-02-26 | (주)휴온스 | Rgd 모티프 함유 펩티드 또는 이의 단편을 포함하는 화상 및 녹내장 치료, 피부 주름 개선 및 발모 촉진용 조성물 |
ES2797901T3 (es) * | 2015-06-28 | 2020-12-04 | Allgenesis Biotherapeutics Inc | Proteínas de fusión para la inhibición de angiogénesis |
AU2016308504A1 (en) | 2015-08-20 | 2018-01-18 | Albumedix Ltd. | Albumin variants and conjugates |
US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US6710030B1 (en) * | 1993-10-22 | 2004-03-23 | University Of Southern California | Contortrostain (CN) and methods for its use in preventing metastasis and other conditions |
US5659018A (en) * | 1995-08-01 | 1997-08-19 | Genetics Institute, Inc. | Mocarhagin, a cobra venom protease, and therapeutic uses thereof |
US20030228298A1 (en) * | 2001-09-04 | 2003-12-11 | Mark Nesbit | Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis |
AU2003248633A1 (en) | 2002-06-07 | 2003-12-22 | Wisconsin Alumni Research Foundation | Chemical synthesis of reagents for peptide coupling |
EP1881849A2 (en) * | 2005-04-29 | 2008-01-30 | Research Development Foundation | Vascular targeting of ocular neovascularization |
US7943728B2 (en) * | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
WO2011011315A1 (en) * | 2009-07-20 | 2011-01-27 | National Cheng Kung University | POLYPEPTIDES SELECTIVE FOR AV β3 INTEGRIN CONJUGATED WITH A VARIANT OF HUMAN SERUM ALBUMIN (HSA) AND PHARMACEUTICAL USES THEREOF |
-
2010
- 2010-12-22 RU RU2012131251/15A patent/RU2012131251A/ru not_active Application Discontinuation
- 2010-12-22 WO PCT/US2010/061738 patent/WO2011079175A1/en active Application Filing
- 2010-12-22 KR KR1020127019529A patent/KR20120130752A/ko not_active Application Discontinuation
- 2010-12-22 NZ NZ600544A patent/NZ600544A/en not_active IP Right Cessation
- 2010-12-22 CA CA2782796A patent/CA2782796A1/en not_active Abandoned
- 2010-12-22 MX MX2012007416A patent/MX2012007416A/es not_active Application Discontinuation
- 2010-12-22 BR BR112012015188A patent/BR112012015188A8/pt not_active IP Right Cessation
- 2010-12-22 US US12/975,630 patent/US9044436B2/en not_active Expired - Fee Related
- 2010-12-22 AR ARP100104891A patent/AR079706A1/es unknown
- 2010-12-22 JP JP2012546185A patent/JP5739908B2/ja not_active Expired - Fee Related
- 2010-12-22 EP EP20100840104 patent/EP2515926A4/en not_active Withdrawn
- 2010-12-22 CN CN2010800594090A patent/CN102883738A/zh active Pending
- 2010-12-22 AU AU2010336475A patent/AU2010336475A1/en not_active Abandoned
- 2010-12-23 TW TW099145616A patent/TWI581801B/zh active
Also Published As
Publication number | Publication date |
---|---|
EP2515926A1 (en) | 2012-10-31 |
US9044436B2 (en) | 2015-06-02 |
JP2013515739A (ja) | 2013-05-09 |
AR079706A1 (es) | 2012-02-15 |
BR112012015188A8 (pt) | 2016-08-09 |
AU2010336475A1 (en) | 2012-06-14 |
JP5739908B2 (ja) | 2015-06-24 |
NZ600544A (en) | 2014-06-27 |
CN102883738A (zh) | 2013-01-16 |
TWI581801B (zh) | 2017-05-11 |
WO2011079175A1 (en) | 2011-06-30 |
US20110152192A1 (en) | 2011-06-23 |
RU2012131251A (ru) | 2014-01-27 |
KR20120130752A (ko) | 2012-12-03 |
EP2515926A4 (en) | 2013-10-09 |
CA2782796A1 (en) | 2011-06-30 |
TW201138801A (en) | 2011-11-16 |
BR112012015188A2 (pt) | 2016-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012007416A (es) | Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis. | |
AR123908A2 (es) | Proteínas de fusión para tratar trastorno metabólicos | |
MX2014001372A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
UA109949C2 (uk) | Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання | |
PH12014500922A1 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
IN2014CN04498A (es) | ||
MY188696A (en) | Cysteine protease | |
BR112014007675A2 (pt) | tratamento de doença articular degenerativa | |
PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
SG196821A1 (en) | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein | |
BR112012017348A2 (pt) | "análogo de peptídeo de oxintomodulina" | |
WO2007038459A3 (en) | Carboxyamine compounds and their use in the treatment of hdac dependent diseases | |
CO6660439A2 (es) | Eliminación de serina proteasa por tratamiento con dióxido de silicona finamente dividido | |
WO2013002580A3 (ko) | 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물 | |
MX2011011130A (es) | Proteina o peptido de fusion con vida media in vivo incrementada mantenido por liberacion in vivo sostenida, y metodo para incrementar la vida media in vivo usando el mismo. | |
MX2010004571A (es) | Composiciones y metodos que comprenden peptidos y proteasas de aminoacidos basicos. | |
MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
NO20082510L (no) | En fremgangsmate for konsentrasjon av et polypeptid | |
EA201491155A1 (ru) | Новые мутантные про-нрф и их применение для получения бета-нрф | |
WO2009064366A3 (en) | Methods and compositions for protein labeling using lipoic acid ligases | |
ECSP10010516A (es) | Uso de variantes de igf-i pegiladas para el tratamiento de trastornos neuromusculares | |
EP2039367A4 (en) | PROPHYLACTIC / THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES | |
NZ601142A (en) | Composition for improving brain function and method for improving brain function | |
WO2011075606A3 (en) | Hyperglycosylated polypeptide variants and methods of use | |
MY168778A (en) | Oligonucleotide chelate complex-polypeptide compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: NATIONAL CHENG KUNG UNIVERSITY.* |
|
FA | Abandonment or withdrawal |